Immunis.AI

Executive Summary

Immunis.AI is a San Francisco-based biotechnology company developing AI-powered diagnostic solutions. Founded in 2019, the company leverages artificial intelligence to analyze multi-omics data—including genomics, proteomics, and metabolomics—to improve disease detection and patient stratification. Its platform aims to translate complex biological data into actionable clinical insights, potentially enabling earlier diagnosis and more personalized treatment decisions. While the company operates in the rapidly growing field of AI-driven diagnostics, public information is limited: no funding rounds, partnerships, or regulatory milestones have been disclosed. The company's stage and valuation remain unknown, and its profile lacks commercial products or clinical trial data. Nevertheless, Immunis.AI's focus on multi-omics integration and AI positions it within a high-potential niche, addressing the need for non-invasive, accurate diagnostic tools. The absence of visible catalysts suggests the company is likely in early development or stealth mode, requiring careful monitoring for any forthcoming announcements.

Upcoming Catalysts (preview)

• Q4 2026Clinical validation study results for lead diagnostic candidate35% success
• H1 2027Strategic partnership with a major diagnostics or pharmaceutical company50% success
• Q3 2026Series A or B funding round announcement70% success